Viking Therapeutics Inc VKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
Trading Information
- Previous Close Price
- $26.84
- Day Range
- $26.51–29.27
- 52-Week Range
- $23.82–43.15
- Bid/Ask
- $28.90 / $28.98
- Shares Outstanding
- 127.52M
- Market Cap
- $3.70B
- Volume/Avg
- 4M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 74
Valuation
Metric | VKTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.28 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VKTX |
|---|---|
Quick Ratio | 7.17 |
Current Ratio | 7.27 |
Interest Coverage | — |
Quick Ratio
VKTX
Profitability
Metric | VKTX |
|---|---|
Return on Assets (Normalized) | −81.31% |
Return on Equity (Normalized) | −101.60% |
Return on Invested Capital (Normalized) | −96.54% |
Return on Assets
VKTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&G&^vpM | LOCK|L!@t% | $140B | |||
| Moderna Inc MRNA | LOCK|?X?q^<& | LOCK|p&^ | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$#!q%d@ | LOCK|?<pLG | $95B | |||
| argenx SE ADR ARGX | LOCK|CGD@h?b | LOCK|<y# | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|##c$TPJ | LOCK|&< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&vG&QXm? | LOCK|>Ff%! | $31B | |||
| Incyte Corp INCY | LOCK|F$>r#? | LOCK|XJd | $25B | |||
| BioNTech SE ADR BNTX | LOCK|x%X!^? | LOCK|>>T | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|NRly>K | LOCK|w&>^ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|sLP@c&$ | LOCK|G> | $16B |
United States